Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a…

With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar…

Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative…

Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer…

Fabian Gerber of SIX Swiss Exchange, Switzerland's principal stock exchange, outlines the importance of life sciences companies to the exchange,…

Professor Ng Huck Hui of A*Star's Biomedical Research Council outlines the evolution of Singapore's science and technology research and innovation…

Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in…

The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals…

John-Arne Røttingen, CEO of The Research Council of Norway shares his career journey from academia to industry, outlines his new role as Norway's…

Anne Kjersti Fahlvik of the Research Council of Norway highlights the health sector’s increasing importance to the Nordic nation, the country’s…

A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates…

The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced…